Meeting
2019 ASCO Annual Meeting
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
Authors
Sarah Sammons
Duke Cancer Institute, Durham, NC
Sarah Sammons , Tira Jing Ying Tan , Tiffany A. Traina , Sung-Bae Kim , Young-Hyuck Im , Carol Bachelder , Paul Kelly Marcom , Rebecca Alexandra Dent
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT03167619
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS1113)
DOI
10.1200/JCO.2019.37.15_suppl.TPS1113
Abstract #
TPS1113
Poster Bd #
187b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).
First Author: Myung-Ju Ahn
Poster
2019 ASCO Annual Meeting
A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
First Author: Zahi Ibrahim Mitri
Poster
2023 ASCO Annual Meeting
Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
First Author: Vaibhav Sahai
Poster
2020 ASCO Virtual Scientific Program
Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
First Author: Navid Hafez